Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy-Reference-Cited by-同舟云学术

Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy

Published:2024 Issue:2 Volume:64 Page:107-118
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:JCEH

Author:

Yagi Yu¹,Kanemasa Yusuke¹,Sasaki Yuki¹,Goto Sotaro²,Yamamura Yasuhiko²,Masuda Yusuke¹,Fujita Kumiko¹,Ishimine Kento¹,Hayashi Yudai¹,Mino Mano¹,Ohigashi An¹,Morita Yuka¹,Tamura Taichi¹,Nakamura Shohei¹,Okuya Toshihiro¹,Matsuda Shinichiro¹,Shimizuguchi Takuya³,Shingai Naoki⁴,Toya Takashi⁴,Shimizu Hiroaki⁴,Najima Yuho⁴,Kobayashi Takeshi⁴,Haraguchi Kyoko⁵,Doki Noriko⁴,Okuyama Yoshiki⁵,Shimoyama Tatsu¹

Affiliation:

1. Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,

2. Department of Pharmacy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,

3. Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,

4. Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,

5. Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Link

https://www.jstage.jst.go.jp/article/jslrt/64/2/64_24009/_pdf

Reference41 articles.

1. 1 Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021; 384: 842-858.

2. 2 Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015; 125: 22-32.

3. 3 Tilly H, Morschhauser F, Sehn LH et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022; 386: 351-363.

4. 4 Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995; 333: 1540-1545.

5. 5 Gisselbrecht C, Glass B, Mounier N et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 4184-4190.